03 Jul, 2020 09:01 AM
SUDA Pharmaceuticals Ltd (ASX: SUD), a leader in oromucosal drug delivery, is pleased to announce that it intends to conduct a 1 for 1 non-renounceable entitlement offer of fully paid ordinary share...read more
25 Jun, 2020 10:35 AM
SUDA Pharmaceuticals Ltd (ASX: SUD), provides the following update in relation to the Company’s recent suspension. The Company had been progressing towards the announcement of a proposed mater...read more
05 Jun, 2020 09:18 AM
The securities of Suda Pharmaceuticals Ltd (‘SUD’) will be suspended from quotation immediately under Listing Rule 17.2, at the request of SUD, pending the release of an announcement reg...read more
20 May, 2020 10:42 AM
SUDA Pharmaceuticals Ltd (ASX: SUD), a leader in oromucosal drug delivery, is pleased to announce that the Japanese Patent Office has now accepted the patent application and the patent will proceed ...read more
30 Apr, 2020 12:03 PM
SUDA Pharmaceuticals Ltd (ASX: SUD), a leader in oromucosal drug delivery, today released its Appendix 4C for the consolidated Group for the third quarter of FY 2020.
During the quarter, Dr Micha...read more
23 Mar, 2020 09:44 AM
SUDA Pharmaceuticals Ltd (ASX: SUD), a leader inoro-mucosal drug delivery, today announces that it has entered into an exclusive licenseagreement with Mitsubishi Tanabe Pharma Korea Ltd (MTPK), a wh...read more
26 Feb, 2020 06:01 PM
Key achievements:
1. SUDA secured three new agreements: Cann Pharma Australia for a novel oral spray of cannabinoid derivatives; and two feasibility studies with Laboratorios Ordesa, S.L. and...read more
31 Jan, 2020 12:29 PM
SUDA Pharmaceuticals Ltd (ASX: SUD), a leader in oro-mucosal drug delivery, today released its Appendix 4C for the consolidated Group for the second quarter of FY 2020. During the quarter, the Compa...read more
09 Dec, 2019 10:56 AM
PERTH, AUSTRALIA – 9 December 2019: SUDA Pharmaceuticals Ltd (ASX:SUD), a leader in oromucosal drug delivery, is pleased to announce that it has entered into a feasibility agreement with SANOF...read more
05 Dec, 2019 08:25 AM
SUDA Pharmaceuticals Ltd (ASX: SUD), a leader in oro-mucosal drug delivery, today announces that it has entered into a fully-funded, feasibility study and option agreement with Laboratorios Ordesa, ...read more
27 Nov, 2019 11:13 AM
Michael Baker joins SUDA Pharmaceuticals from the leading Australian life science fund, Bioscience Managers, where he was based from 2017. As an Investment Manager, he was responsible for deal sourc...read more
18 Nov, 2019 11:11 AM
SUDA Pharmaceuticals (ASX:SUD), a leader in oro-mucosal drug delivery, is pleased to advise that it has received a refund of $927,970 from the Australian Taxation Office under the R&D Tax In...read more
